Moving on to CBD and THC, new cannabinoids are on the way.
A new study published has revealed the discovery of two previously unknown cannabinoids, now called THCP and CBDP. In tests on mice, the researchers found that THCP had “an affinity for the CB1 receptor more than 30 times greater than that reported for THC,” making it much more potent than THC.
Although researchers have so far identified about 150 cannabinoids in cannabis, the majority of studies have focused on the two most apparently useful – CBD and THC. THC is the component of the plant that gets users high, while CBD has many of the therapeutic benefits of THC without the accompanying buzz. The emergence of equally or more potent cannabinoids will likely lead to further studies and, hopefully, commercialization.
“Several clinical trials and a growing number of publications provide real evidence of the pharmacological potential of cannabis and cannabinoids on a wide range of disorders from sleep to anxiety, multiple sclerosis, autism, and neuropathic pain,” said the researchers. “In particular, being the most potent of the psychotropic cannabinoids, THC is the main focus of these studies”.
“THCP has an even higher binding affinity for the CB1 receptor and greater cannabimimetic activity than THC itself.”
Kevin McKernan, the Scientific Director of Medicinal Genomics, tweeted the study, referring to the new cannabinoid as “more potent than THC”. Can we just grow hemp with THCP gobs?”
The discovery of THCP could also help explain the amazing pharmacological properties of certain strains of cannabis that previously could not be attributed to the presence of THC alone, the researchers said.
As for CBDP, the researchers said that the poor ability of cannabinoids to bind to CB1 or CB2 receptors does not make further exploration of its cannabimimetic activity a priority. But the opposite is true for THCP, which researchers say has enormous potential for medical use.
“In our opinion, this compound should be included in the list of major Phytocannabinoids to be determined for a proper evaluation of the pharmacological effect of cannabis extracts administered to patients”.